Analysts expect Tiziana Life Sciences to report zero revenue and a consensus EPS loss of $0.03, with the current stock price of $1.03 trading significantly below the $9.18 average analyst price target. Investors are primarily focused on clinical updates regarding the Phase 2a INFORM-MS trial for intranasal foralumab, which recently completed patient enrollment in May 2026.
Following the successful dosing of the final patient in the na-SPMS study, the market is awaiting management's commentary on safety profiles and cash runway ahead of topline data expected in late Q3. Recent positive PET imaging results in related neurodegenerative trials have bolstered sentiment, shifting focus toward the company's ability to fund its expanding pipeline through 2027.